BMRN Stock Overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$117.27 |
| 52 Week High | US$117.77 |
| 52 Week Low | US$70.73 |
| Beta | 0.36 |
| 1 Month Change | 13.32% |
| 3 Month Change | 35.37% |
| 1 Year Change | 36.11% |
| 3 Year Change | 40.44% |
| 5 Year Change | 29.12% |
| Change since IPO | 793.49% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09
Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?
Oct 29Are Investors Undervaluing BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) By 49%?
Sep 24I Ran A Stock Scan For Earnings Growth And BioMarin Pharmaceutical (NASDAQ:BMRN) Passed With Ease
Aug 27Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?
Jul 10BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 19A Look At The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
May 03Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Apr 01The BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Has Gained 12% And Shareholders Are Hoping For More
Feb 17
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 21% Discount?
Jan 22We're Not Counting On BioMarin Pharmaceutical (NASDAQ:BMRN) To Sustain Its Statutory Profitability
Dec 22Shareholder Returns
| BMRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.9% | 0.8% | 2.8% |
| 1Y | 36.1% | 7.1% | -9.2% |
Return vs Industry: BMRN exceeded the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: BMRN exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| BMRN volatility | |
|---|---|
| BMRN Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BMRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BMRN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,045 | Jean-Jacques Bienaime | https://www.biomarin.com |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| BMRN fundamental statistics | |
|---|---|
| Market Cap | US$21.79b |
| Earnings (TTM) | US$83.91m |
| Revenue (TTM) | US$2.01b |
259.7x
P/E Ratio10.9x
P/S RatioIs BMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMRN income statement (TTM) | |
|---|---|
| Revenue | US$2.01b |
| Cost of Revenue | US$476.13m |
| Gross Profit | US$1.53b |
| Other Expenses | US$1.45b |
| Earnings | US$83.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 76.29% |
| Net Profit Margin | 4.18% |
| Debt/Equity Ratio | 23.7% |
How did BMRN perform over the long term?
See historical performance and comparison